---
title: Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
date: '2024-05-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38809174/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240529181055&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In patients with mixed hyperlipidemia, zodasiran was associated
  with significant decreases in triglyceride levels at 24 weeks. (Funded by Arrowhead
  Pharmaceuticals; ARCHES-2 ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with mixed hyperlipidemia, zodasiran was associated with significant decreases in triglyceride levels at 24 weeks. (Funded by Arrowhead Pharmaceuticals; ARCHES-2 ClinicalTrials.gov number, ...